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ABSTRACT
Small ubiquitin-like modifier (SUMO) is used by the intrinsic antiviral immune response to restrict viral pathogens, such as her-
pes simplex virus 1 (HSV-1). Despite characterization of the host factors that rely on SUMOylation to exert their antiviral effects,
the enzymes that mediate these SUMOylation events remain to be defined.We show that unconjugated SUMO levels are largely
maintained throughout infection regardless of the presence of ICP0, the HSV-1 SUMO-targeted ubiquitin ligase. Moreover, in
the absence of ICP0, high-molecular-weight SUMO-conjugated proteins do not accumulate if HSV-1 DNA does not replicate.
These data highlight the continued importance for SUMO signaling throughout infection. We show that the SUMO ligase pro-
tein inhibitor of activated STAT 4 (PIAS4) is upregulated during HSV-1 infection and localizes to nuclear domains that contain
viral DNA. PIAS4 is recruited to sites associated with HSV-1 genome entry through SUMO interactionmotif (SIM)-dependent
mechanisms that are destabilized by ICP0. In contrast, PIAS4 accumulates in replication compartments through SIM-indepen-
dent mechanisms irrespective of ICP0 expression. Depletion of PIAS4 enhances the replication of ICP0-null mutant HSV-1,
which is susceptible to restriction by the intrinsic antiviral immune response. The mechanisms of PIAS4-mediated restriction
are synergistic with the restriction mechanisms of a characterized intrinsic antiviral factor, promyelocytic leukemia protein, and
are antagonized by ICP0.We provide the first evidence that PIAS4 is an intrinsic antiviral factor. This novel role for PIAS4 in
intrinsic antiviral immunity contrasts with the known roles of PIAS proteins as suppressors of innate immunity.
IMPORTANCE
Posttranslational modifications with small ubiquitin-like modifier (SUMO) proteins regulate multiple aspects of host immunity
and viral replication. The protein inhibitor of activated STAT (PIAS) family of SUMO ligases is predominantly associated with
the suppression of innate immune signaling. We now identify a unique and contrasting role for PIAS proteins as positive regula-
tors of the intrinsic antiviral immune response to herpes simplex virus 1 (HSV-1) infection. We show that PIAS4 relocalizes to
nuclear domains that contain viral DNA throughout infection. Depletion of PIAS4, either alone or in combination with the in-
trinsic antiviral factor promyelocytic leukemia protein, significantly impairs the intrinsic antiviral immune response to HSV-1
infection. Our data reveal a novel and dynamic role for PIAS4 in the cellular-mediated restriction of herpesviruses and establish
a new functional role for the PIAS family of SUMO ligases in the intrinsic antiviral immune response to DNA virus infection.
Intrinsic antiviral immunity is the first line of intracellular de-fense to viral infection. This defense is mediated by constitu-
tively expressed cellular proteins that cooperatively act to restrict
the progression of infection (reviewed in references 1 to 4). How-
ever, viruses have evolved mechanisms to counteract this host
response to ensure their efficient replication and spread.
During herpes simplex virus 1 (HSV-1) infection, viral gene
expression occurs in a tightly regulated temporal cascade consist-
ing of immediate early (IE), early (E), and late (L) gene products.
IE proteins play pivotal roles in modulating the intracellular en-
vironment in order to facilitate viral replication, including inacti-
vation of host immunity thatwould otherwise restrict the progres-
sion of infection (reviewed in reference 5). One key aspect of
intrinsic immunity to HSV-1 infection is the rapid recruitment of
constitutively expressed restriction factors to nuclear sites associ-
ated with viral genomes following their nuclear entry (6–8). Left
unimpeded, the stable recruitment of such factors is sufficient to
restrict HSV-1 gene expression and facilitate the transcriptional
silencing of viral genomes to block lytic replication (6, 7, 9–13).
Restriction factors recruited to infecting viral genomes include
core constituent proteins of promyelocytic leukemia (PML) nu-
clear bodies (PML-NBs; also known as nuclear domain 10
[ND10]), proteins involved in the DNA damage response (DDR),
and the nuclear DNA pathogen sensor IFI16 (6, 7, 11, 12, 14–16).
The small ubiquitin-like modifier (SUMO) pathway (17–19) me-
diates the recruitment of PML-NB-associated restriction factors,
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although to what extent this pathway is involved in the recruit-
ment of other restriction factors remains unknown.
The posttranslational modification (PTM) of proteins with
SUMO regulates numerous cellular processes, including multiple
aspects associated with virus infection and host immunity (re-
viewed in references 3, 20, and 21). Three predominant SUMO
isoforms (SUMO1 to -3) are ubiquitously expressed and conju-
gated within mammalian cells. SUMOylation is analogous to
ubiquitination, requiring an E1 activating complex (SAE1/2), an
E2 conjugation enzyme (Ubc9), and E3 ligases that impart sub-
strate specificity (reviewed in references 22 and 23). SUMO2 and
SUMO3 (here referred to as SUMO2/3) share 97% amino acid
identity and can form polymeric SUMO chains (24). SUMO1
shares 46% amino acid identity with SUMO2 and is typically
associated with single modification or the termination of
poly-SUMO chains (24). Proteins can be deSUMOylated by
SUMO-specific proteases (reviewed in references 25 and 26).
SUMOylation therefore provides a highly dynamic mechanism
that enables the cell to quickly respond to various stimuli by alter-
ing protein stability, functionality, or intracellular localization.
Following nuclear entry of HSV-1 genomes, de novo SUMO
conjugates accumulate adjacent to viral genomes in a Ubc9-de-
pendent manner (18). This stimulates the recruitment of constit-
uent PML-NB restriction factors, including PML, Sp100, and
Daxx, through SUMO-dependent protein-protein interactions
mediated by their respective SUMO interaction motifs (SIMs)
(17, 18). Importantly, the recruitment of these host factors occurs
independently of PML and is inhibited by Ubc9 depletion, high-
lighting a key role for the SUMOpathway in this aspect of intrinsic
immunity (18). The HSV-1 IE protein ICP0, a viral SUMO-tar-
geted ubiquitin ligase (STUbL), counteracts this host response by
inducing the degradation of PML-NB constituent, and other
SUMO-conjugated, proteins through a combination of SUMO-
dependent and -independent targeting mechanisms (3, 18, 19,
27–30). ICP0-mediated proteasome-dependent degradation or
dispersal of restriction factors away from infecting viral genomes
enables the progression of viral gene expression and the onset of
lytic replication (reviewed in reference 31). HSV-1 mutants that
lack, or express catalytically inactive, ICP0 are thereforemore sus-
ceptible to cellular restriction and are likely to enter into a non-
productive (quiescent) infection. A high multiplicity of infection
(MOI) with ICP0-null mutant HSV-1 is sufficient, however, to
saturate and overcome this host response (reviewed in reference
31). Under such conditions, the onset of infection results in a
global induction of high-molecular-weight (HMW) SUMO-con-
jugated proteins (18, 19). However, the SUMO ligases responsible
for regulating these nuclear responses to infection remain to be
defined.
In contrast to the ubiquitin pathway, the SUMOylation of
cellular proteins is regulated by a relatively small number of E3
ligases, the best-characterized and largest family of which is the
protein inhibitor of activated STAT (PIAS1 to -4) family. These
ligases were initially characterized as negative regulators of in-
nate immunity by virtue of their transrepression of key regula-
tors in the interferon (IFN) pathway (32–37). However, mem-
bers of this family have subsequently been shown to play
important roles in the regulation of many other cellular pro-
cesses, including PML stability (38), transcription (39), DNA
repair (40–42), NF-B regulation (43, 44), the cell cycle (45,
46), and senescence (47). PIAS family members contain several
evolutionarily conserved domains and motifs that mediate nu-
clear matrix binding (SAP), noncovalent SUMO interaction
(SIM), nuclear retention (PINIT), transrepression activity
(LxxLL), and SUMO ligase activity (Siz PIAS [SP] RING) (re-
viewed in references 48 and 49). Due to the varied nature of nu-
clear substrates and cellular processes that PIAS proteins are re-
ported to regulate, we investigated if members of this family
mediated aspects relating to intrinsic antiviral immunity to
HSV-1 infection. We report that PIAS4 localized to sites associ-
ated with viral DNA throughout infection. Following nuclear en-
try of viral genomes, PIAS4 relocalized to the nuclear periphery in
a SIM-dependent manner. The stable association of PIAS4 at foci
associated with infecting viral genomes was inhibited by ICP0.
PIAS4 also accumulated in viral replication compartments, irre-
spective of ICP0 expression, in a SAP domain- and LxxLL motif-
dependent manner. Depletion of PIAS4 did not affect the replica-
tion ofwild-typeHSV-1 but significantly enhanced the replication
of ICP0-null mutant HSV-1. Codepletion of PIAS4 and PML en-
hanced the relief in cellular restriction, indicating that PML and
PIAS4 independently contribute to the restriction of ICP0-null
mutant HSV-1.We therefore identify a unique role for PIAS4 as a
positive regulator of intrinsic antiviral immunity to HSV-1 infec-
tion and uncover a previously unknown role for this family of
SUMO ligases in the cellular restriction of DNA viruses.
MATERIALS AND METHODS
Cells, drugs, and viruses. Human osteosarcoma (U2OS) cells, human
embryonic kidney (HEK-293T) cells, and primary human foreskin fibro-
blasts (HFs) (Department of Urology, University of Erlangen [50]) were
maintained at 37°C in 5% CO2 in Dulbecco’s modified Eagle medium
(DMEM; Life Technologies; 41966) supplemented with 10% fetal bovine
serum (FBS; Life Technologies; 10270), 100 U/ml of penicillin, and 100
g/ml of streptomycin (Life Technologies; 15140-122). HFt cells are im-
mortalized human foreskin fibroblasts stably transduced with retrovirus
that expresses the catalytic subunit of human telomerase, as described
previously (51). The plaque-forming efficiency of wild-type or ICP0-null
mutant HSV-1 strains in HFt cells is similar to that in HFs cells (data not
shown).
Phosphonoacetic acid (PAA; Sigma-Aldrich; 284270) prepared at 100
mg/ml in DMEMwas used at 400g/ml. Acycloguanosine (ACG; Sigma-
Aldrich; A4669) prepared at 50 mM in Milli-Q H2O was used at 50 M.
MG132 (Calbiochem; 474790) prepared at 10 mM in dimethyl sulfoxide
(DMSO; Sigma-Aldrich; D2650) was used at 10 M. Doxycycline (DOX;
Sigma-Aldrich; D9891) prepared at 1 mg/ml in Milli-Q H2O was used at
0.1 g/ml. Cycloheximide (CHX; Sigma-Aldrich; C-7698) prepared at 5
mg/ml in Milli-Q H2O was used at 10 g/ml. For transgenic cells, hygro-
mycin (Invitrogen; 10687-010), puromycin (Puro; Sigma-Aldrich;
P8833), or neomycin (Neo; Sigma-Aldrich; A1720) was used at 50g/ml,
1g/ml, or 1mg/ml, respectively, during selection or 5g/ml, 0.5g/ml,
or 0.5 mg/ml, respectively, for maintenance.
Wild-type HSV-1 strain 17syn, its ICP0-null mutant derivative
dl1403 (52), and their respective variants that express eYFP.ICP4 (53)
were used. All viruses were propagated and titrated as described previ-
ously (54). When used, MG132, PAA, or ACG was added following a 1-h
inoculum adsorption.
Plasmids and lentiviral transduction. The FLAG sequence in
FLAG.PIAS4, a generous gift fromMaryDasso (NIH, Bethedsa,MD), was
replaced with an enhanced yellow fluorescent protein (eYFP) coding se-
quence, and the resultant eYFP.PIAS4 expression construct was sub-
cloned into the lentiviral vector pLKO.dCMV.TetO/R (55) via NheI and
SalI restriction sites. PIAS4 mutations and deletions performed by PCR
mutagenesis are described in Table 1. All clones were confirmed by se-
quencing. His-tagged SUMO2, a generous gift from BenHale (University
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of Zurich), was subcloned into the lentiviral vector pLVX.neo (Invitro-
gen) via Xhol and Xbal restriction sites. Plasmids that express short hair-
pin RNAs (shRNAs) against PML (shPML) or a control sequence (shCtrl)
are described elsewhere (18, 50). Of the five tested shRNAs against PIAS4
(Sigma-Aldrich), shP4_3 (based on 5=-AATTCGGTGGGCTTCAGCA-
3=) had the best levels of depletion and was selected for use.
Lentiviral supernatant stocks were generated andHFt cells were trans-
duced as described previously (50). Pooled stably transduced cells were
used for experimentation.
Antibodies. Primary rabbit antibodies included anti-actin (Sigma-
Aldrich; A5060), anti-enhanced green fluorescent protein (anti-eGFP;
Abcam; ab290), anti-Daxx (Upstate; 07-471), anti-PIAS1 (LsBio; LS-
B9173), anti-PIAS2 (LsBio; LS-C108717), anti-PIAS3 (LsBio; LS-
C98795), anti-PIAS4 (LsBio; LS-C108719), anti-PML (Bethyl Laborato-
ries; A301-167A), anti-Sp100 (SpGH [56]), anti-SUMO1 (Abcam;
ab32058), and anti-SUMO2/3 (Abcam; ab22654) antibodies. Primary
mousemonoclonal antibodies included anti-His (Abcam; ab18184), anti-
ICP0 (11060 [57]), anti-ICP4 (58s [58]), anti-SUMO1 (Invitrogen; 33-
2400), anti-SUMO2/3 (Abcam; ab81371), anti-UL42 (Z1F11 [59]), and
anti-VP5 (DM165 [60]) antibodies. Secondary antibodies included Dy-
Light 680- or 800-conjugated anti-rabbit or -mouse (Thermo) antibodies;
Alexa 488-, 555-, or 633-conjugated anti-rabbit, -sheep, or -mouse (In-
vitrogen) antibodies; and peroxidase-conjugated anti-mouse antibodies
(Sigma-Aldrich; A4416).
Plaque forming efficiency (PFE). HFt cells (1  105 per well) in 24-
well plates were incubated at 37°C in 5% CO2 overnight or at least 4 h
prior to infection. Wild-type or ICP0-null mutant HSV-1 was serially
diluted in serum-free DMEM. Cells inoculated with sequential viral dilu-
tions were rocked and rotated every 10min for 1 h and then overlaid with
37°C cell appropriate medium supplemented with 2% human serum
(HS). At 24 to 26 h postinfection (hpi), cells were washed twice in phos-
phate-buffered saline (PBS; Sigma-Aldrich; D1408), fixed in 1.8% form-
aldehyde (Sigma-Aldrich; F8775) and 0.1% NP-40 (BDH; 56009) in PBS
for 10 min, and then washed twice in 0.1% Tween in PBS (PBST). Cells
were blocked with 5% skim milk powder (SMP; Marvel) in PBST for 30
min before incubation with anti-VP5 diluted in 5% SMP in PBST for 90
min. Cells were washed in PBST three times, incubated with peroxidase-
conjugated anti-mouse IgG diluted in 5% SMP in PBST for 60 min, and
then washed in PBST threemore times. Plaques were visualized with True
Blue peroxidase developing solution (Insight; 50-78-02) according to the
manufacturer’s instructions.
Western blotting. HFt cells were washed twice with room tempera-
ture PBS and then lysed and collected in SDS-PAGE loading buffer with 4
M urea (Sigma-Aldrich; U0631) and 50 mM dithiothreitol (DTT; Sigma-
Aldrich; D0632). Whole-cell lysates were immediately used or snap-fro-
zen. Proteins resolved using standard Tris-glycine or Tris-tricine SDS-
PAGE systems were electrotransferred onto 0.2-m nitrocellulose
membranes (Amersham; 15249794) for 150 (Tris-tricine) or 180 (Tris-
glycine) min at 250 mA in Towbin buffer (25 mM Tris, 192 mM glycine,
20% [vol/vol] methanol) at room temperature. Membranes were blocked
in 5% newborn calf serum (NCS) in PBS at 4°C overnight. Subsequent
steps were performed at room temperature on a roller apparatus. Mem-
branes were incubated in primary antibody diluted in 5% NCS in PBST
for 2 h, washed in PBST three times for 5 min each, then incubated in
secondary antibody diluted 1:10,000 in 5% NCS in PBST for 1 h. Follow-
ing three 5-min washes in PBST, one 5-min wash in PBS, and one rinse in
Milli-Q H2O, membranes were imaged on an Odyssey infrared imager
(LiCor). The intensity of protein bands was quantified with Odyssey Im-
age Studio software.
Immunofluorescence and confocal microscopy. HFt cells (1 105)
seeded on 13-mmglass coverslips in 24-well plates were incubated at 37°C
in 5% CO2 overnight. For infections, wild-type or ICP0-null mutant
HSV-1 was diluted in serum-free DMEM to the multiplicity of infection
(MOI) indicated in the corresponding figure legends. Cells were typically
infected at a low MOI for 16 to 24 h in order to examine the recruitment
of host factors to nuclear sites associated with HSV-1 genome entry or
replication compartments in cells at the periphery of a developing plaque
(6). Inoculum was adsorbed for 1 h at 37°C in 5% CO2, with rocking and
rotating every 10 min, prior to the addition of 37°C cell-appropriate me-
diumwith 2%HS. Fixation and immunostainingwere performed at room
temperature. Cells were washed twice in CSK (10 mM HEPES, 100 mM
NaCl, 300 mM sucrose, 3 mMMgCl2, 5 mM EGTA), fixed and permeab-
ilized in 1.8% formaldehyde and 0.5% Triton X-100 (Sigma-Aldrich;
T-9284) in CSK for 10 min, and then washed in CSK three times. Cover-
slips were blocked with 2%HS in PBS for 10min, incubated with primary
antibodies diluted in 2% HS in PBS for 90 min, and then washed in PBS
three times. Cells were then incubated with 4=,6-diamidino-2-phenylin-
dole (DAPI; Sigma-Aldrich; D9542) and secondary antibodies diluted
1:1,000 in 2% HS in PBS for 60 min, washed in PBS three times, and
washed twice in Milli-Q H2O. Coverslips were mounted on glass slides
using a glycerol-basedmountingmedium (Citifluor; AF1) sealedwith nail
enamel. Cells were examined using Zeiss LSM 510 or LSM 710 confocal
microscopes with 405-nm, 488-nm, 543-nm, and 633-nm laser lines un-
der a 63 Plan-Apochromat oil immersion lens with a numerical aper-
ture of 1.4. For graphing purposes, pixel intensities were acquired using
Zen software (Zeiss). Exported images were processed with minimal ad-
justment using Adobe Photoshop and assembled for presentation using
Adobe Illustrator.
Quantitative reverse transcription-PCR (RT-PCR). A total of 1.5
105 or 2 105 HFt cells seeded in 12-well plates were incubated at 37°C in
5%CO2 overnight or at least 4 h before further manipulation. Total RNA
was isolated using theRNAeasy Plus kit (Qiagen; 74134) or TRIzol reagent
(Invitrogen; 15596) according to the manufacturer’s instructions. RNA
was reverse transcribed using the TaqMan reverse transcription reagent
kit (Life Technologies; N8080234) with oligo(dT) primers. Samples were
analyzed in triplicate using TaqMan Fast Universal PCRmaster mix (Life
Technologies; 4352042) with the following TaqMan gene-specific primer
(6-carboxyfluorescein [FAM]/MGB)-probe mixes (Life Technologies):
PML (assay IDHs00231241_m1), PIAS4 (assay IDHs00249203_m1), 18S
(GenBank accession number X03205.1; Thermo Fisher Scientific;
TABLE 1 PCR primers used for the mutation or deletion of conserved domains within PIAS4
PIAS4
mutant Forward primer Reverse primer
Amino acid sequence
change
C342A 5=-TGCCGGGCAGAGACCGCCGCCCACCTGCAGT 5=-ACTGCAGGTGGGCGGCGGTCTCTGCCCGGCA C to A
mLxxLL 5=-TCAGATGGCCGCGGGTTTCGTGGGCCGGAGTA 5=-CCGCGGCCATCTGAAGGTCGGAGACT LQMLL to LQMAA
SAP (N) 5=-TAACGCTAGCACCATGGTGAGC 5=-GGCTCCGAGTTCTTCTTGGCCATCCGGGAAT
TCGAAGCTT
Deletion encompassing
A2 to A67
SAP (C) 5=-GCCAAGAAGAACTCGGAGCC 5=-TTAGTCGACCCGTCAGCAGGCCGGCACCA
mPINIT 5=-CGCCCCGCCAACGCCACTCAC 5=-GTGAGTGGCGTTGGCGGGGCG PINIT to PANAT
mSIM 5=-GATGCGGCGGACCTCACGCTGGACAGCTC 5=-GACCTCCGCCGCATCGGCGCCCGGCTTCC VVDLT to AADLT
C34 5=-TTTTTGCTAGCACCATGGTGAGCAAG 5=-TTTTGTCGACTCACGAGGACGATGA Stop codon introduced
after S476
PIAS4 Is an Intrinsic Antiviral Factor
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4319413E), or glyceraldehyde-3-phosphate dehydrogenase (GAPDH;
GenBank accession number NM_002046.5; Thermo Fisher Scientific;
4333764F).
RESULTS
HMW SUMO-conjugated protein levels increase when HSV-1
DNA replicates. Whether or not the steady-state levels of un-
conjugated free SUMO were altered during HSV-1 infection
along with the global changes in SUMOylation was evaluated.
Consistent with previous reports (18), HMW SUMO1- or SU-
MO2/3-conjugated protein levels decreased during wild-type
HSV-1 infection, while they increased during ICP0-null mu-
tant HSV-1 infection (Fig. 1A and B, HMW). Although the
levels of HMWSUMO-conjugated proteins were clearly altered
in an ICP0-dependent manner, the levels of unconjugated free
SUMO1 or -2/3 remained relatively stable (Fig. 1A and B, free).
In HFt cells infected with 10 PFU per cell of wild-type or ICP0-
null mutant HSV-1, the cellular pools of free SUMO1 or -2/3
were depleted by 20 to 30% at 9 hpi (Fig. 1A and B, free). In
contrast, inhibition of the proteasome, in either the presence or
absence of ICP0, was sufficient to deplete the pools of free
SUMO1 or -2/3 by 70 to 80% (Fig. 1A and B, MG132). To-
gether, these data indicate that free SUMO levels are likely
regulated during infection, irrespective of the broad depletion
or accumulation of HMW SUMO-conjugated proteins during
wild-type or ICP0-null mutant HSV-1 infection, respectively.
Moreover, these data suggest that free SUMO levels are un-
likely to be a limiting factor for de novo SUMOylation, support-
ing the concept that dynamic SUMO modification and signal-
ing occur throughout infection (28).
In the absence of ICP0, the accumulation of HMW SUMO-
conjugated proteins wasmost prominent at later times after infec-
tion (Fig. 1A and B, 9 hpi). To evaluate whether HSV-1 DNA
replication or late (L) protein expression contributed to this accu-
mulation, HFt cells were infected with 10 PFU per cell of ICP0-
nullmutantHSV-1 in the presence or absence of phosphonoacetic
acid (PAA) to inhibit the HSV-1 DNA polymerase, or acy-
cloguanosine (ACG) to inhibit nascentDNA synthesis (61–64). In
the absence of viral DNA replication, the levels of HMWSUMO1-
or SUMO2/3-conjugated proteins, as well as the levels of free
SUMO1 or SUMO2/3, remained similar to those in mock-in-
fected cells (Fig. 1C). The SUMOylation events that result in the
accumulation of HMWSUMO-conjugated proteins therefore oc-
cur whenHSV-1DNA replicates or L proteins are expressed. Viral
transcription in general, or the expression of IE or E proteins, was
not sufficient to stimulate this broad accumulation of HMW
SUMO-conjugated proteins during ICP0-null mutant HSV-1 in-
fection.
PIAS4 localizes to HSV-1 replication compartments. To
investigate the potential significance of the accumulation of
HMW SUMO-conjugated proteins during ICP0-null mutant
HSV-1 infection, the SUMO E3 ligase(s) that could mediate
these SUMOylation events was analyzed, starting with the PIAS
protein family. Consistent with other reports, PIAS proteins in
HFt cells were predominantly nuclear, with microspeckled dis-
tributions characteristic of localization at matrix-associated
regions (MARs) (Fig. 2A to D, mock) (65–67). While a subpop-
ulation of PIAS1 localized to PML-NBs, substantial localization
of PIAS2, PIAS3, or PIAS4 at these structures was not detected in
this cell type (Fig. 2A to D, mock, and data not shown) (38, 66).
PIAS4 robustly relocalized to viral replication compartments,
whereas PIAS1, PIAS2, and PIAS3 did not (Fig. 2A to D). The
relocalization of PIAS4 was independent of ICP0, as it occurred
during wild-type or ICP0-null mutant HSV-1 infection (Fig. 2D).
PIAS4 is thus identified as a SUMO E3 ligase that accumulates in
herpesvirus replication compartments. SUMO2/3 also accumu-
lated in HSV-1 replication compartments, although only in the
FIG 1 HMW SUMO-conjugated proteins do not accumulate when HSV-1 DNA does not replicate. (A) Western blots show the levels of HMW-
conjugated or free SUMO1 or -2/3 during wild-type or ICP0-null mutant HSV-1 infection. HFt cells infected with 10 PFU of wild-type or ICP0-null
mutant (ICP0) HSV-1 per cell in the presence () or absence () of the proteasome inhibitor MG132 were harvested at 3, 6, or 9 h postinfection (hpi).
Membranes were probed for SUMO1 or -2/3, the viral protein ICP0 or UL42 to monitor infection progression, or actin as a loading control. Molecular
mass markers are indicated, in kilodaltons. (B) Bar graphs show the average relative levels of HMW-conjugated or free SUMO1 or -2/3 during wild-type
or ICP0-null mutant HSV-1 infection. The intensities of SUMO1 or -2/3 protein bands were quantitated from Western blots as shown in panel A;
quantitated levels were normalized to their respective loading controls and are expressed relative to the levels in mock-infected cells at 9 hpi (1.0). Means
and standard error of the means (SEM) are shown (n  4). (C) Bar graphs show the average relative levels of HMW-conjugated or free SUMO1 or -2/3
in the presence of either of the DNA replication inhibitors PAA or ACG, MG132, or no drug (ND). Infections equivalent to those for panel A were
performed in the presence or absence of the indicated drugs. The intensities of SUMO1 or -2/3 protein bands were quantitated from Western blots;
quantitated values were normalized to their respective loading controls and are expressed relative to the levels in untreated mock-infected cells at 9 hpi.
Means and SEM are shown (n  3). *, P  0.05; **, P  0.01 (Student’s two-tailed t test).
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absence of ICP0 (Fig. 2E). Therefore, during ICP0-null mutant
HSV-1 infection, the majority of nuclear PIAS4 and SUMO2/3
localize in replication compartments.
Multiple domains mediate PIAS4 localization at MARs. To
investigate the roles of PIAS4 during HSV-1 infection, the do-
mains that mediate recruitment into replication compartments
were evaluated (Fig. 3A). While the SAP domain regulates
MAR association (65, 66), the LxxLL sequence, PINIT domain,
SIM, or carboxyl (C)-terminal acidic domain (AD) may medi-
ate important protein-protein interactions that regulate PIAS4
localization during infection (Fig. 3A). Additionally, the cata-
lytic activity of PIAS4 may regulate localization through the
FIG 2 PIAS4 accumulates in HSV-1 replication compartments. (A to D) Confocal images show the nuclear localization of PIAS1 (A), PIAS2 (B), PIAS3 (C), or
PIAS4 (D) in HFt cells mock infected (mock) or infected with 0.002 PFU of wild-type HSV-1 or 2 PFU of ICP0-null mutant (ICP0) HSV-1 per cell for 16 h.
Wild-type and mutant HSV-1 strains expressed eYFP-ICP4, the accumulation of which was used to visualize replication compartments within cells at the edge
of developing plaques (6). PIAS proteins were visualized by indirect immunofluorescence (red). Insets (dashed boxes in panel D) highlight regions of PIAS4
localization within replication compartments. (E) Confocal images show the nuclear localization of PIAS4 and SUMO2/3 within wild-type or ICP0-null mutant
HSV-1 replication compartments in cells infected as described above. ICP4 (green), PIAS4 (red), and SUMO2/3 (cyan) were visualized by indirect immuno-
fluorescence. Nuclei were visualized by DAPI (blue).
PIAS4 Is an Intrinsic Antiviral Factor
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FIG 3 HFt cells stably transduced with DOX-inducible eYFP.PIAS4 wild-type or mutant protein expression constructs. (A) The illustration depicts the
conserved PIAS4 domains (gray boxes) mutated within eYFP.PIAS4 (eYFP.P4) (Table 1). (B) Confocal images show the nuclear expression of eYFP, eYFP.P4
wild-type (wt) or mutant proteins (as indicated) in transgenic HFt cells after 8 h of induction (DOX) or not (DOX). Nuclei were visualized by DAPI (blue).
(C) Western blot shows the levels of eYFP.PIAS4 wild-type (eYFP.P4 wt) or endogenous PIAS4 (PIAS4) in transgenic HFt cells after different lengths of DOX
induction, as indicated.Membranes were probed for PIAS4 or actin as a loading control. The asterisk indicates a PIAS4 polyclonal antibody cross-reacting band.
(D) A bar graph shows the average level of eYFP.P4 wt relative to endogenous PIAS4 in transgenic cells after various lengths of DOX induction. The intensities
of PIAS4 protein bands fromWestern blots as in panel C were quantitated and normalized to their respective loading controls. Normalized levels of eYFP.P4 wt
are expressed relative to the normalized levels of endogenous PIAS4 at each time. Means and standard deviations (SD) are shown (n	 3). (E)Whole-cell lysates
collected from transgenicHFt cells 8 h post-DOX inductionwere analyzed byWestern blotting for the levels of eYFP and eYFP.PIAS4wild-type ormutant protein
(as indicated) expression. Membranes were probed for eYFP or actin as a loading control. (F) Western blot shows the levels of eYFP.PIAS4 wild-type or
catalytically inactivemutant (C342A) proteins at different times after translational inhibition. Expression of eYFP.P4wt or eYFP.P4.C342AwasDOX induced for
4 h prior to the replacement of DOXwith the translation inhibitor cycloheximide (CHX) in the presence () or absence () of MG132.Whole-cell lysates were
harvested at 0, 2, 4, 6, or 8 h following CHX addition. Membranes were probed with eYFP or actin as a loading control. Molecular mass markers are indicated,
in kilodaltons. (G)Abar graph shows the average relative levels of eYFP.PIAS4wild-type or catalytically inactivemutant proteins following translation inhibition.
The intensities of protein bands corresponding to eYFP.P4 quantitated fromWestern blots as in panel F were normalized to their respective loading controls and
expressed relative to the normalized levels at 0 h of CHX treatment (1.0). Means and SEM are shown (n	 3). (H) A bar graph shows the average relative levels
of PIAS4 mRNA in transgenic cells that express eYFP.P4 wild-type or catalytically inactive mutant proteins. Total RNA was isolated after 4, 8, or 24 h of DOX
induction. The levels of PIAS4mRNAwere determined using the TaqMan system of quantitative RT-PCR. Values were normalized to GAPDH expression using
the threshold cycle (CT)method and are expressed relative to the normalized level of PIAS4mRNA at 0 h of DOX induction (1). Values represent the averages
from two independent experiments. (I) A bar graph shows the average relative level of endogenous PIAS4 following translation inhibition. HFt cells were treated
with CHX in the presence () or absence () of MG132, and whole-cell lysates were collected at 2, 4, or 8 h after CHX addition. Intensities of the protein bands
corresponding to PIAS4 were quantitated and normalized to their respective loading controls and are expressed relative to the normalized level of PIAS4 at 0 h
of CHX treatment (1.0). Means and SEM are shown (n 3).
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SUMOylation of substrates to influence relevant protein-pro-
tein interactions.
A panel of lentiviral vectors that encode eYFP fused to PIAS4
with pointmutations or deletions in the aforementioned domains
was constructed (Table 1; Fig. 3A). To regulate expression of the
eYFP.PIAS4wild-type ormutant proteins, transcriptional control
was placed under the control of a doxycycline (DOX)-inducible
promoter. HFt cells stably transduced with the eYFP.PIAS4 ex-
pression constructs did not have detectable eYFP expression in the
absence ofDOX,whereas greater than 90%of transduced cells had
detectable eYFP fluorescence following DOX induction (Fig. 3B).
As expected, the relative levels of eYFP fusion protein expression
increased with induction time (Fig. 3C andD). The ectopic PIAS4
proteins were of the expected molecular weight; however, several
mutant proteins had lower expression levels than the wild-type
eYFP.PIAS4 (Fig. 3E). At least for the catalytically inactive mu-
tant, eYFP.P4.C342A, lower expression levels resulted from de-
creased protein abundance rather than reduced transcript ex-
pression (Fig. 3F to H). Endogenous PIAS4 and eYFP.PIAS4
were more stable than eYFP.P4.C342A, suggesting that the cat-
alytically inactive mutant protein was likely inherently unsta-
ble (Fig. 3F and I).
EYFP.PIAS4 protein levels increased substantially with time,
without considerable alteration to endogenous PIAS4 expression
(Fig. 3C and D). As noted in other studies, however, high levels of
ectopic PIAS4 had detrimental cellular effects (66, 68). Overex-
pression of eYFP.PIAS4 drastically affected SUMO signaling ho-
meostasis, increasing HMW SUMO-conjugated protein levels at
least 4-fold and decreasing free SUMO levels 5-fold following 24 h
of induction (Fig. 4A and B). Consequently, dynamic SUMO
modification was affected, which resulted in a loss of constitutive
PML and Sp100 SUMOylation and disrupted PML-NBs (Fig. 4C
to E), a phenotype similar to that in Ubc9-depleted cells (18).
Consistently, the disruption of SUMO pathway homeostasis was
attributed to PIAS4-mediated global depletion of free SUMO
pools, as these effects did not occur when catalytically inactive
PIAS4 was expressed or when His-tagged SUMO2 was expressed
concomitantly with eYFP.PIAS4 to supplement the free SUMO2
pools (Fig. 4). To avoid gross disruption of SUMO pathway equi-
librium, expression of the wild-type andmutant eYFP.PIAS4 pro-
teins was typically induced for only 6 to 8 h, which did not sub-
stantially alter SUMO pathway homeostasis (Fig. 4A and B).
Amino-terminal fusion of eYFP did not adversely affect PIAS4
subnuclear localization (Fig. 5B). Inactivation of PIAS4 SUMO
ligase activity (C342A), deletion of the SAP domain, or mutation
of the LxxLLmotif or SIMdisruptedPIAS4MAR localization (Fig.
5C to E and G). In contrast to the catalytically inactive or SIM
mutant proteins, however, the SAP and mLxxLL mutants local-
ized to PML-NBs (Fig. 5D and E). Mutation of the PINIT motif
resulted in an intermediate phenotype, with subpopulations of
PIAS4 localized at PML-NBs or nuclear diffuse (Fig. 5F), suggest-
ing that this motif stabilizes either localization. Deletion of the
C-terminal AD (C34) caused a nuclear diffuse and cytoplasmic
localization, implicating this domain in nuclear retention or
transport of PIAS4 (Fig. 5I).
These data demonstrate that all of the conserved domains of
PIAS4 contribute to its characteristic MAR localization in HFt
cells. In the absence of stable PIAS4 localization atMARs, the SIM
or catalytic activity promotes localization at PML-NBs. TheC-ter-
minal AD of PIAS4 is required to stabilize PIAS4 localization at
either MARs or PML-NBs and contributes to the predominantly
nuclear localization of PIAS4.
PIAS4 can colocalize with PML in ICP0-null mutant HSV-1
replication compartments in a SIM-dependent manner. The
subnuclear localization of mutant eYFP.PIAS4 proteins was ini-
tially evaluated during ICP0-null mutant HSV-1 infection to
avoid potential ICP0-mediated disruption of relevant interac-
tions. EYFP alone did not accumulate in replication compart-
ments, while eYFP.PIAS4 did (Fig. 6A and B), demonstrating that
fusion to eYFP did not adversely affect PIAS4 localization. How-
ever, endogenous PIAS4 tended to localize throughout individual
replication compartments, whereas eYFP.PIAS4 tended to occupy
subdomains within them (Fig. 6B and J). Notably, endogenous or
exogenous PIAS4 could colocalize with PML, a known intrinsic
antiviral factor (Fig. 6B, K, and L). The regions where eYFP.PIAS4
and PML colocalized were largely restrained to subdomains
within individual replication compartments and often resembled
string-like structures (Fig. 6B, inset) (69).
Themutant eYFP.PIAS4 proteins all accumulated in ICP0-null
mutant HSV-1 replication compartments, although they had dif-
ferent localization phenotypes within them (Fig. 6C to I). As for
wild-type eYFP.PIAS4, the SAP, mLxxLL, mPINIT, C34, and
C342A mutant proteins could colocalize with PML (Fig. 4B to F
and I). These regions of colocalization also tended to occupy sub-
domains within individual replication compartments, sometimes
resembled string-like structures (69), and were not necessarily
present within every replication compartment of any given cell.
The colocalization of eYFP.PIAS4 mLxxLL, SAP, or mPINIT
mutants with PML in ICP0-null mutant HSV-1-infected cells was
not unanticipated given that these mutants localized to PML-NBs
in uninfected cells (Fig. 5D to F). Conversely, the eYFP.PIAS4
C342A and C34 mutants only colocalized with PML in infected
cells (compare Fig. 5C and I to 6C and I), which highlights a
differential requirement for the ligase activity or the C-terminal
AD of PIAS4 for colocalization with PML in uninfected cells.
Mutation of the PIAS4 SIM disrupted localization to PML-
containing subdomainswithin replication compartments (Fig. 6G
andH), consistent with the SIM-mediated localization of PIAS4 at
PML-NBs in uninfected cells (Fig. 5G). In the absence of SIM-
mediated interactions, PIAS4 still localized within replication com-
partments; however, it was homogenously distributed and tended to
localize within all of the replication compartments of any given cell
(Fig. 6G).Mutation of the SIM in conjunction with the LxxLLmotif
reduced PIAS4 accumulationwithin ICP0-nullmutantHSV-1 repli-
cation compartments (Fig. 6H), indicating that the LxxLLmotif also
contributes to this localization phenotype.
These data demonstrate that PIAS4 can colocalize with PML
within ICP0-null HSV-1 replication compartments, sometimes in
string-like structures. The differential colocalization of PIAS4
with PML in cells that have been infected or not indicates that
PIAS4 localization is differentially regulated during infection.
While the SIM mediates colocalization with PML, such colocal-
ization is not strictly required for PIAS4 accumulation in ICP0-
nullmutantHSV-1 replication compartments. This observation is
consistent with multiple mechanisms to regulate PIAS4 sub-
nuclear localization during infection.
PIAS4 accumulation in wild-type HSV-1 replication com-
partments is largelymediated by the SAP domain or LxxLLmo-
tif.The SIM-mediated colocalization of PIAS4with PMLwas pre-
dominant, although not necessary for PIAS4 localization within
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replication compartments. The direct or indirect association of
PIAS4 with PML could therefore conceal relevant interactions
mediated by the other domains of PIAS4 that contribute to repli-
cation compartment localization. To address this possibility, the
localization of wild-type and mutant eYFP.PIAS4 proteins was
evaluated during wild-type HSV-1 infection, when ICP0 effi-
ciently mediates PML degradation (70, 71). As for ICP0-null mu-
tant HSV-1 infection, eYFP did not accumulate in wild-type
FIG 4 Overexpression of eYFP-PIAS4 disrupts SUMO pathway homeostasis. (A) Western blots show the levels of HMW-conjugated or free SUMO1 or -2/3 in
transgenic HFt cells induced () to express eYFP or eYFP.PIAS4 wild-type (wt) or catalytically inactive mutant (C342A) proteins or not (). Whole-cell lysates
were collected at 4, 8, or 24 h postinduction. Membranes were probed for SUMO1 or -2/3, eYFP, or actin as a loading control. (B) Bar graphs show the average
levels of HMW-conjugated or free SUMO1 or -2/3 in transgenic cells induced () or not () to express eYFP or eYFP.PIAS4 wild-type or catalytically inactive
mutant proteins. The intensities of protein bands corresponding to SUMO1 or -2/3 quantitated from Western blots as in panel A were normalized to their
respective loading control and expressed relative to the levels in uninduced cells (1.0). Means and SEM are shown (n	 2 [HMW] or n	 3 [free]). (C)Western
blots show the SUMOmodification of PML or Sp100 in transgenic cells induced () or not () to express eYFP or eYFP.PIAS4wild-type or catalytically inactive
mutant proteins for 24 h. Membranes were probed for SUMO2/3, eYFP, PML, Sp100, or actin as a loading control. (D) Confocal images show PML-NBs in
transgenic cells induced to express eYFPor eYFP.PIAS4wild-type or catalytically inactivemutant proteins. PML-NBswere identified byPMLaccumulation; PML
was visualized by indirect immunofluorescence (red). (E) Box-and-whisker chart shows the number of PML-NBs per nuclei in transgenic cells induced (DOX)
for 24 h or not (DOX) to express eYFP or eYFP.PIAS4 wild-type or catalytically inactive mutant proteins. Boxes, 25th to 75th percentile; black line, median
number of PML-NBs per nucleus; whiskers, absolute range. The total number of cells analyzed per sample is indicated by each box from10 fields of view per
sample collected over two independent experiments. ***, P  0.0001 (Mann-Whitney U test). (F) A Western blot shows the SUMO modification of PML in
transgenic cells induced to express eYFP.P4 wt in the presence or absence of His-SUMO2. HFt cells stably transduced with eYFP.P4 expression vectors were
transduced with a second lentiviral vector to constitutively express His-tagged SUMO2 or with an empty vector control. Expression of eYFP.P4 was induced for
0, 4, 8, or 24 h prior to the collection of whole-cell lysates. Membranes were probed for His, eYFP, PML, or actin as a loading control. Molecular mass markers
are indicated, in kilodaltons.
FIG 5 PIAS4 relocalizes to PML-NBs in a SIM- or ligase-dependent manner in the absence of SAP- or LxxLL-mediated interactions. Confocal images show the
localization of eYFP or eYFP.PIAS4 wild-type or mutant proteins with respect to PML-NBs after 6 to 8 h of DOX induction. PML-NBs were identified by PML
accumulation; PML was visualized by indirect immunofluorescence (red). Nuclei were visualized by DAPI (blue).
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HSV-1 replication compartments, whereas eYFP.PIAS4 did (Fig.
7A and B). The accumulation of eYFP.PIAS4 within wild-type
HSV-1 replication compartments confirms that this localiza-
tion is not disrupted by ICP0 and occurs independently of
PML. EYFP-PIAS4 was distributed throughout wild-type
HSV-1 replication compartments, similar to the distribution of
endogenous PIAS4 (Fig. 7J). This distribution differed from
that of eYFP.PIAS4 in ICP0-null mutant HSV-1 replication
compartments, where it localized to subdomains within indi-
vidual replication compartments (compare Fig. 6J and 7J).
These data suggest that although fusion with eYFP does not
adversely affect PIAS4 accumulation in replication compart-
ments, it may stabilize the SIM-mediated association of PIAS4
with PML. SIM-dependent interactions, however, were not es-
FIG 6 PIAS4 can associate with PML in ICP0-null mutant HSV-1 replication compartments in a SIM-dependent manner. (A to I) Confocal images show
the nuclear localization of eYFP or eYFP.PIAS4 wild-type or mutant proteins (as indicated) with respect to ICP0-null mutant (ICP0) HSV-1 replication
compartments, identified by ICP4 accumulation, or PML. Transgenic HFt cells were infected with 1 PFU of ICP0-null mutant HSV-1 per cell for 16 h prior
to DOX induction of eYFP or eYFP.PIAS4 wild-type or mutant protein expression for 6 to 8 h. Localization of PML (cyan) and ICP4 (red) was visualized
by indirect immunofluorescence. The inset (dashed box in panel B) highlights a region within a replication compartment where eYFP.P4 wt and PML
colocalize in string-like structures (69). (J) Validation of PIAS4 polyclonal antibody (pAb; cyan) detection of eYFP.P4 wt within ICP0-null mutant HSV-1
replication compartments (ICP4; red). (K) Confocal images show the association of endogenous PIAS4 (red) with PML (cyan) in ICP0-null mutant
HSV-1 replication compartments. (L) Emission spectra depict the pixel intensity and colocalization between eYFP.ICP4, endogenous PIAS4, and PML
within a focus or region of an ICP0-null mutant HSV-1 replication compartment indicated by the corresponding numbered lines in panel K. Nuclei were
visualized by DAPI (blue).
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sential for PIAS4 localization in ICP0-null or wild-type HSV-1
replication compartments (Fig. 6G and 7G). Furthermore, it
should be noted that eYFP fusion in itself did not promote
association with PML (Fig. 5B).
The eYFP.PIAS4 C342A, mPINIT, and C34 mutants local-
ized to wild-type HSV-1 replication compartments (Fig. 7C, F,
and I). The PINIT motif likely facilitates PIAS4 accumulation
within replication compartments, as mutation of this motif in-
creased the proportion of PIAS4 that was located outside of them
(Fig. 7F). Mutation of the LxxLL motif or deletion of the SAP
domain markedly reduced eYFP.PIAS4 accumulation within
wild-type HSV-1 replication compartments, demonstrating that
these domains largely facilitate or stabilize PIAS4 localization
within them (Fig. 7D and E).
These data confirm that the localization of PIAS4 in HSV-1
replication compartments is not disrupted by ICP0. Whereas the
PINIT motif promotes or stabilizes PIAS4 accumulation within
replication compartments, the SAP domain or LxxLL motif con-
siderably enhances it. However, as demonstrated during ICP0-
null mutant HSV-1 infection, additional factors are sufficient for
PIAS4 localization in replication compartments in the absence of
a functional SAP domain or LxxLL motif.
PIAS4 is recruited to domains that contain infecting HSV-1
genomes in a SIM-dependentmanner that is disrupted by ICP0.
During ICP0-null mutant HSV-1 infection, eYFP.PIAS4 also lo-
calized to nuclear domains that contained infecting viral genomes
(Fig. 8B) (6, 8, 69). This localization was SIM dependent (Fig. 8C
to I), consistent with the SIM-dependent recruitment of evaluated
constituent PML-NB antiviral proteins (17). However, high levels
of eYFP.PIAS4 expression disrupted the SIM-dependent recruit-
ment of constituent PML-NB antiviral proteins without disrupt-
ing its own recruitment (Fig. 9). The global depletion of free
SUMO pools as a consequence of high levels of eYFP.PIAS4 ex-
pression likely precluded the de novo SUMOylation events that
mediate recruitment of constitutive PML-NB antiviral proteins
(Fig. 4A and B and 9) (17, 18). In contrast, de novo SUMOylation,
higher levels of free SUMO, or constituent PML-NB antiviral pro-
teins were not required for the recruitment of eYFP-PIAS4 to
domains that contained infecting HSV-1 genomes (Fig. 9A).
Moreover, under conditions of depleted free SUMO pools,
eYFP.PIAS4 was not sufficient to recruit constituent PML-NB an-
tiviral proteins to nuclear domains that contained infecting
HSV-1 genomes (Fig. 9).
EYFP.PIAS4was recruited to domains that contained infecting
FIG 7 The SAP domain or LxxLLmotif enhances PIAS4 accumulation inwild-typeHSV-1 replication compartments. (A to I) Confocal images show the nuclear
localization of eYFP or eYFP.PIAS4 wild-type or mutant proteins (as indicated) with respect to wild-type HSV-1 replication compartments, identified by ICP4
accumulation. Transgenic HFt cells were infected with 0.002 PFU of wild-type HSV-1 per cell for 16 h prior to DOX induction of eYFP or eYFP.PIAS4 wild-type
or mutant protein expression for 6 to 8 h. ICP4 (red) and PML (cyan) were visualized by indirect immunofluorescence. The inset (dashed box in panel B)
highlights the punctate localization of eYFP.P4 wt within a replication compartment. (J) Validation of PIAS4 pAb (cyan) detection of eYFP.P4 wt within
wild-type HSV-1 replication compartments (ICP4; red). Nuclei were visualized by DAPI stain (blue).
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HSV-1 genomes prior to the detectable expression of the IE pro-
tein ICP4 (Fig. 8J), indicating that recruitment occurs shortly after
viral genomes enter the nucleus. Consistently, eYFP.PIAS4 was
also recruited to nuclear domains that contained infecting wild-
type HSV-1 genomes, although only prior to ICP0-mediated dis-
ruption of the intrinsic antiviral immune response as denoted by
PML degradation (Fig. 8N and O). The redistribution of endoge-
nous PIAS4 to sites associated with infecting HSV-1 genomes was
not readily detected by immunofluorescence, although it could be
observed on rare occasion (Fig. 8K andM). These data suggest that
the recruitment of endogenous PIAS4 to domains that contain
infecting HSV-1 genomes may be transient or unstable. Nonethe-
less, even in the absence of marked accumulation, endogenous
PIAS4 could be detected in some foci that contained ICP4 and
thus HSV-1 genomes by proxy (Fig. 8K and L).
These data demonstrate that PIAS4 is recruited through SIM-
dependent mechanisms to nuclear domains associated with
HSV-1 genome entry. The recruitment of constituent PML-NB
antiviral proteins to these domains is not a prerequisite for PIAS4
recruitment, nor is PIAS4 sufficient to facilitate the recruitment of
constituent PML-NB antiviral proteins when free SUMO pools
are depleted. The recruitment of eYFP.PIAS4 under conditions of
depleted free SUMO pools is consistent with a mechanism that is
largely independent of de novo SUMOylation. Nonetheless, ICP0
FIG 8 ICP0 disrupts PIAS4 SIM-dependent recruitment to nuclear domains associated with HSV-1 genome entry. (A to I) Confocal images show the nuclear
localization of eYFP or eYFP.PIAS4 wild-type or mutant proteins (as indicated) with respect to infecting ICP0-null mutant (ICP0) HSV-1 genomes, visualized
by the asymmetric nuclear edge localization of ICP4 or PML (6, 69). Transgenic HFt cells were infected with 1 PFU of ICP0-null mutant HSV-1 per cell for 16
h prior to DOX induction of eYFP or eYFP.PIAS4 wild-type or mutant protein expression for 6 to 8 h. ICP4 (red) and PML (cyan) were visualized by indirect
immunofluorescence. (J) Validation of PIAS4 pAb (cyan) detection of eYFP.P4 wt at nuclear domains that contain infecting HSV-1 genomes. (K and M)
Confocal images show the typical (K) or atypical (M) localization of endogenous PIAS4 (red) with respect to eYFP.ICP4 at a nuclear edge associated with
ICP0-nullmutantHSV-1 genomenuclear entry. (L) Emission spectra depict pixel intensity and colocalization between eYFP.ICP4 and PIAS4 in selected foci that
correspond to the numbered lines in panel K. (N) Confocal images show the localization of eYFP.P4 wt with respect to PML or ICP4 in cells at the periphery of
a developing wild-type HSV-1 plaque. Transgenic HFt cells were infected with 0.002 PFU of wild-type HSV-1 per cell for 16 h prior to induction of eYFP.P4 wt
for 6 to 8 h. ICP4 (red) and PML (cyan) were visualized by indirect immunofluorescence. The arrow highlights the asymmetric redistribution of eYFP.P4 wt or
PML to the nuclear edge prior to the detectable expression of ICP4. (O) Confocal images show the localization of eYFP.P4 wt with respect to ICP0 or PML prior
to ICP0-mediated degradation of PML. Transgenic HFt cells were infected as for panel N. ICP0 (red) and PML (cyan) were visualized by indirect immuno-
fluorescence. Nuclei were visualized by DAPI (blue).
FIG 9 Overexpression of eYFP.PIAS4 disrupts the recruitment of PML-NB antiviral proteins to domains that contain infecting HSV-1 genomes in an
SP-RING-dependent manner. (A and B) Confocal images show the recruitment of constituent PML-NB antiviral proteins to nuclear domains associated with
HSV-1 genome entry in transgenic cells that express eYFP.PIAS4wild-type (wt; A) or catalytically inactivemutant (C342A; B) proteins. TransgenicHFt cells were
induced with DOX for 16 h before they were infected with 1 PFU of ICP0-null mutant (ICP0) HSV-1 per cell for 24 h. The nuclear domains that contain
infecting HSV-1 genomes were identified by nuclear edge localization of ICP4. PML, Sp100, Daxx, SUMO1, or SUMO2/3 (cyan) and ICP4 (red) were visualized
by indirect immunofluorescence.
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is sufficient to disrupt the stable localization of PIAS4 at nuclear
domains that contain infecting HSV-1 genomes.
PIAS4 protein levels increase with the progression of HSV-1
infection. The accumulation of endogenous PIAS4 inHSV-1 rep-
lication compartments increased in prominence as infection pro-
gressed, which could result from accumulation of PIAS4, an in-
crease in PIAS4 protein expression, or both. The expression levels
of PIAS4 were therefore evaluated in HFt cells infected with 10
PFU per cell of wild-type or ICP0-null mutant HSV-1. As infec-
tion progressed, endogenous PIAS4 protein levels increased (Fig.
10A and B). This increase was most prominent during wild-type
infection, demonstrating that PIAS4 is not a target for ICP0-me-
diated degradation (Fig. 10A and B). Inhibition of the proteasome
did not further enhance PIAS4 protein levels (Fig. 10A and B,
MG132), indicating that this increase was largely not achieved
through changes to PIAS4 turnover rates. AlthoughPIAS4 protein
levels increased, PIAS4 mRNA levels remained largely unchanged
(Fig. 10C), supporting the notion that PIAS4 does not correspond
to an interferon-stimulated gene (ISG) (72). Together, these data
suggest that the increase in PIAS4 protein levels is likely the result
of changes to its translational or posttranslational regulation
rather than changes to its transcription or protein turnover rates.
PIAS4 restricts ICP0-null mutant HSV-1 replication
throughmechanisms complementary toPML-mediated restric-
tion. PIAS4 expression increased during HSV-1 infection, and it
localized to nuclear domains that contained viral genomes. Fur-
thermore, PIAS4 colocalized with known intrinsic antiviral fac-
tors during ICP0-null mutant HSV-1 infection. To test the func-
tional significance of PIAS4 during infection, replication of wild-
type or ICP0-nullmutantHSV-1was evaluated in cells depleted of
PIAS4 or of PML as a positive control (50). To this end, HFt cells
were transduced with lentiviral vectors that expressed short hair-
pin RNAs (shRNAs) against PIAS4, PML, or a nontargeted scram-
bled control. Cells that expressed PML-specific shRNAs had a
marked depletion in PML protein and mRNA levels, while cells
that expressed PIAS4-specific shRNAs had considerable, although
not complete, depletion of PIAS4 protein and mRNA levels (Fig.
11A andB). As PIAS4 is integral for cell division (45), the degree of
PIAS4 depletion varied with each round of transduction, and after
limited passaging, PIAS4 protein levels recovered to those in cells
transduced with control shRNAs (data not shown). All functional
experiments were therefore conducted over multiple rounds of
independent transduction with minimal passaging following the
isolation of stably transduced cells.
PML depletion did not affect the relative plaque forming effi-
ciency (PFE) of wild-type HSV-1 and increased that of ICP0-null
mutant HSV-1, as expected (Fig. 11C) (50). Depletion of PIAS4
did not noticeably affect the replication of wild-typeHSV-1, dem-
onstrating that PIAS4 is not essential for HSV-1 replication (Fig.
11C and D). PIAS4 depletion did, however, enhance the replica-
tion of ICP0-null mutant HSV-1 (Fig. 11C and E). In PIAS4-
depleted cells, the PFE of ICP0-null mutant HSV-1 was enhanced
10-fold (Fig. 11C, ICP0). Furthermore, the expression and ac-
cumulation of viral proteins from all kinetic classes were increased
in transgenic cells that expressed shPIAS4 relative to those in cells
that expressed shCtrl (Fig. 11E). These data indicate that PIAS4 is
an intrinsic antiviral factor that contributes to the cellular restric-
tion of ICP0-nullmutantHSV-1.However, expression of shRNAs
against PIAS4 variably reduced PML expression (Fig. 11B and F
and data not shown). These effects on PML were not a conse-
quence of the specific sequence of the shRNA against PIAS4, as
other evaluated PIAS4-specific shRNAs had similar effects (data
not shown). Given the variable effects on PML expression when
PIAS4 was depleted, it was possible that unintentional depletion
of PML contributed to the relief of restriction of ICP0-nullmutant
HSV-1 replication in these cells. To address this possibility, repli-
cation of wild-type and ICP0-nullmutantHSV-1was evaluated in
cells codepleted of PIAS4 and PML. HFt cells stably cotransduced
with shRNAs against PML and PIAS4 had considerable depletion
of both targets (Fig. 11F). Codepletion of PIAS4 and PML did not
substantially alter the PFE of wild-type HSV-1, supporting the
conclusions that PIAS4 is nonessential for HSV-1 replication and
that any PIAS4-mediated antiviral activities are counteracted by
ICP0 (Fig. 11G, HSV-1). Conversely, codepletion of PIAS4 and
PML substantially enhanced the PFE of ICP0-null mutant HSV-1
to an even greater degree than depletion of either protein alone
(Fig. 11G, ICP0). These data confirm that PIAS4 contributes to
the restriction of ICP0-null mutant HSV-1 and demonstrate that
FIG 10 Endogenous PIAS4 expression increases during HSV-1 infection. (A) A Western blot shows PIAS4 levels during wild-type or ICP0-null mutant
HSV-1 infection. HFt cells mock infected or infected with 10 PFU of wild-type or ICP0-null mutant (ICP0) HSV-1 per cell in the presence () or absence
() of MG132 were harvested at 3, 6, or 9 hpi. Membranes were probed for PIAS4, either of the viral proteins ICP0 and UL42 to indicate infection
progression, or actin as a loading control. Molecular mass markers are shown, in kilodaltons. (B) A bar graph shows the average levels of PIAS4 in
wild-type or ICP0-null mutant HSV-1-infected cells. The intensities of PIAS4 protein bands quantitated fromWestern blots as in panel A were normalized
to their respective loading controls and expressed relative to the normalized level in mock-infected cells at 9 hpi (1.0). Means and SEM are shown (n 	
7). *, P 0.05 (Student’s two-tailed t test). (C) A bar graph depicts the average relative level of PIAS4mRNA during wild-type or ICP0-null mutant HSV-1
infection. HFt cells were infected as described for panel A, and total RNA was isolated at 9 hpi. PIAS4 mRNA levels were determined using the TaqMan
system of quantitative RT-PCR. Values normalized to GAPDH expression using the CT method are expressed relative to mock-infected cells (1.0).
Means and SEM are shown (n  3).
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FIG 11 Endogenous PIAS4 contributes to the cellular restriction of ICP0-null mutant HSV-1. (A)Western blots show the levels of PIAS4 or PML in transgenic
HFt cells that express short hairpin RNAs against PIAS4 (shPIAS4), PML (shPML), or a control sequence (shCtrl). Membranes were probed for PIAS4, PML, or
actin as a loading control. (B) A bar graph shows the average relative levels of PIAS4 or PML mRNA in transgenic HFt cells that express shCtrl, shPIAS4, or
shPML. PIAS4 or PMLmRNA levels were determined using the TaqMan system of quantitative RT-PCR. Values normalized to 18S expression using the CT
method are expressed relative to cells that expressed shCtrl (1.0). Values represent means and SD from three independent rounds of RT using mRNA isolated
from one representative experiment. (C) A bar graph shows the average relative plaque formation efficiency (PFE) of wild-type or ICP0-null mutant (ICP0)
HSV-1 in transgenic cells that express shCtrl, shPIAS4, or shPML, as indicated. The PFE for each strain in cells that express shPIAS4 or shPML was normalized
to the respective PFE in cells that express shCtrl (1). Means and SD are shown (n 3). (D and E)Western blots show the levels of viral protein expression during
wild-type or ICP0-null mutant (ICP0) HSV-1 infection of transgenic HFt cells that express shCtrl or shPIAS4. Transgenic cells mock infected or infected with
10 PFU of wild-type (D) or ICP0-null mutant (E) HSV-1 per cell in the presence () or absence () ofMG132 were harvested at 3, 6, or 9 hpi. Membranes were
probed for ICP4, ICP0, UL42, or VP5 to monitor the progression of infection or actin as a loading control. Molecular mass markers are shown, in kilodaltons.
(F) A bar graph shows the average relative levels of PML or PIAS4 mRNA in transgenic cells that express shCtrl, shPIAS4, or shPML alone or in combination, as
indicated. Analysis was performed as for panel B. Neo, neomycin resistance; Puro, puromycin resistance. (G) A bar graph shows the average relative PFE of
wild-type or ICP0-null mutant HSV-1 in transgenic HFt cells that express shCtrl, shPIAS4, or shPML alone or in combination, as indicated. PFE analysis was
done as described for panel C. Means and SD are shown (n 3).
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the restrictive roles of PIAS4 are synergistic with those of PML.
The SUMO E3 ligase PIAS4 is thus identified as an intrinsic anti-
viral factor.
DISCUSSION
We show that PIAS4 is upregulated and localizes to nuclear do-
mains that contain viral genomes during HSV-1 infection. The
recruitment of PIAS4 to domains that contain infecting HSV-1
genomes is SIM dependent, whereas its accumulation in replica-
tion compartments is largely mediated by its SAP domain or
LxxLLmotif. However, in the absence of ICP0, the SAP domain or
LxxLL motif is dispensable for PIAS4 localization in replication
compartments, as the SIM mediates colocalization with PML
within them. PIAS4 contributes to the restriction of ICP0-null
mutant HSV-1 through mechanisms that are synergistic with
those of PML. We thus identify PIAS4 as an intrinsic antiviral
factor. This unique role for PIAS4 adds to the current understand-
ing of PIAS proteins as immune regulators and warrants future
investigation into their novel roles as intrinsic antiviral factors that
restrict DNA virus infection.
Neither the STUbL-like activities of ICP0 nor the accumula-
tion of HMW SUMO-conjugated proteins in the absence of ICP0
is sufficient to fully deplete the free SUMO pools during infection
(Fig. 1A and B). Maintenance of free SUMO levels would uphold
SUMO pathway integrity and permit the SUMO modification of
specific targets throughout infection (28). SUMOylation could
thus be utilized to influence the outcome of infection over the
course of infection. Importantly, these data suggest that although
ICP0 promotes the degradation of specific SUMOylated proteins,
the SUMO moiety itself may not be degraded (18, 19, 28). Alter-
natively, SUMO protein expressionmay be upregulated (73). The
almost full depletion (by 80 to 90%) of free SUMO following the
overexpression of eYFP.PIAS4 or inhibition of the proteasome is
in stark contrast to the levels of depletion during HSV-1 infection
(20 to 30%) (Fig. 1B and 4B) and supports the concept that free
SUMO pools are regulated during infection. Consistently, the
broad changes in protein SUMOylation observed during HSV-1
infection would require a functional SUMOylation pathway and
free SUMO (18, 28).
SUMO signaling is vital for the cellular restriction of ICP0-null
mutant HSV-1. SUMO-SIM interactions regulate the individual
recruitment of certain antiviral factors, including PIAS4 and con-
stituent PML-NB antiviral proteins, to nuclear domains that con-
tain infecting HSV-1 genomes (this study and reference 17). To
our knowledge, the SIM-dependent recruitment of PIAS4 repre-
sents the first example of a nonconstituent PML-NB protein re-
cruited in this manner. Disruption of de novo SUMOylation
events, for example, throughUbc9 depletion, significantly impairs
intrinsic immunity by hindering the recruitment of individual
PML-NB antiviral proteins to domains that contain infecting
HSV-1 genomes (17, 18). We now show that depletion of free
SUMO pools also disrupts the recruitment of constituent
PML-NB antiviral proteins to such domains, which further sup-
ports a requisite for new SUMOylation events in this process (Fig.
4B and 9). In contrast, the recruitment of (eYFP) PIAS4 to do-
mains that contain infecting HSV-1 genomes is not adversely af-
fected by the depletion of free SUMO pools (Fig. 9). This obser-
vation highlights a differential requirement for free SUMO in the
mechanisms of recruitment for constituent PML-NB antiviral
proteins and PIAS4. In the absence of relevant SIM-mediated in-
teractions, other PIAS4 domains may be sufficient to mediate its
recruitment. Alternatively, different SIM-dependent mechanisms
of recruitment may exist, for example, through interactions with
existing versus newly SUMOylated targets. Even so, ICP0 is suffi-
cient to disrupt the stable localization of PIAS4 at nuclear domains
associated with HSV-1 genome entry.
In the absence of ICP0, it is tempting to relate the localization
of SUMO2/3 and PIAS4 in viral replication compartments to the
accumulation of HMW SUMO-conjugated proteins. Of the rela-
tively few SUMO E3 ligases identified, PIAS4 is the only one eval-
uated that extensively localizes within HSV-1 replication com-
partments (Fig. 2; also evaluated were RanBP2 and KAP1 [data
not shown]). However, how PIAS4 catalytic activity is regulated,
or if PIAS4 even mediates SUMOylation events during infection,
is not yet known. It will be interesting to determine if the antiviral
activities of PIAS4 are indeed accomplished through its catalytic
activity, as SUMO ligation is dispensable for many of its charac-
terized functions (34, 66–68, 74–84). The localization of PIAS4 at
nuclear domains that contain HSV-1 DNA occurs independently
of its catalytic activity, and its roles at these sites may also be
independent of SUMO ligation. During ICP0-null mutant HSV-1
infection, the accumulation ofHMWSUMO-conjugated proteins
was not substantially altered in PIAS4-depleted cells relative to
that in their transduction controls (data not shown). This obser-
vation could argue that PIAS4 is not the sole or primary SUMOE3
ligase to catalyze these SUMOylation events. However, the levels
of PIAS4 depletion may not have been to a degree that would
detectably alter the accumulation of HMW SUMO-conjugated
proteins within the population of depleted cells. Further investi-
gation into the regulation of PIAS4 catalytic activity and the iden-
tification of potential PIAS4 substrates in infected cells is war-
ranted.
Stabilization of certain domain-mediated interactions over
others could provide a rapid and dynamic means to alter PIAS4
subnuclear localization or binding partners to quickly respond to
changing nuclear conditions. In noninfected HFt cells, the inter-
actions that mediate PIAS4 MAR association are favored over
those that mediate localization at other nuclear domains, such as
PML-NBs (Fig. 5). During infection with ICP0-null mutant
HSV-1, PIAS4 SIM-mediated direct or indirect interactions with
PML predominate (Fig. 6B and G and 8B and G), suggesting that
infection enhances PIAS4 SIM-mediated interactions over those
mediated by its other domains. Whereas the PIAS4 SIM-depen-
dent recruitment to nuclear domains that contain infecting
HSV-1 genomes is efficiently disrupted by ICP0, its SAP domain-
or LxxLL motif-mediated accumulation in replication compart-
ments is not (Fig. 2D and 8B and N). The ICP0-sensitive recruit-
ment of PIAS4 to domains that contain infecting HSV-1 genomes
suggests that this is where PIAS4 exerts its antiviral activities. Con-
sequently, the ICP0-mediated degradation or dispersal of relevant
SUMOylated proteins to prevent PIAS4 recruitment could effi-
ciently counteract PIAS4 antiviral activities (18). However, the
potential for PIAS4-mediated antiviral roles within replication
compartments cannot be ruled out. Multiple mechanisms to re-
cruit PIAS4 into replication compartments may represent a cellu-
lar antiviral “failsafe” or could indicate that PIAS4 has multiple
roles during infection. An overarching theme in the characterized
functions of PIAS4 is the availability of cellular cofactors or sub-
nuclear localization to dictate PIAS4 activity in any given role,
which supports the plausibility of the latter scenario. PIAS4 dif-
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ferentially localizes within replication compartments in the pres-
ence or absence of ICP0 (compare Fig. 6B and J to 7B and J), which
corroborates the concept that PIAS4 has different interaction
partners under these different infection conditions. However,
PIAS4 is only restrictive in the absence of ICP0 (Fig. 11C and G).
Thus, ICP0 could also counteract the antiviral activities of PIAS4
within replication compartments by disrupting relevant PIAS4 inter-
actions or localization within them. Identification of PIAS4 inter-
action partners during wild-type or ICP0-null mutant HSV-1 in-
fection will aid in understanding how PIAS4 contributes to
intrinsic antiviral immunity and how its antiviral effects are coun-
teracted by ICP0.
The increase in PIAS4 protein expression during infection is
most likely achieved through changes in its translational or post-
translational regulation (Fig. 10). The 3= untranslated region of
PIAS4 mRNA has mir-29 and let-7 microRNA family comple-
mentary sites (TargetScanHuman release 7.0 [85]). Downregula-
tion of mir-29 or let-7 during infection provides one means
whereby PIAS4 translation could be altered to increase protein
expression (73, 86–88). As infection progresses, ICP0 accumulates
in the cytoplasm, where it antagonizes IRF3-mediated transacti-
vation (89, 90). The upregulation of PIAS4 could aid in the repres-
sion of innate immunity through PIAS4-mediated antagonism of
STAT and NF-B transactivation (34, 43). Moreover, PIAS4 also
directly binds to and represses IRF3, which could provide an
added level of IRF3 suppression during infection (37, 78).
PIAS proteins were initially characterized as negative regula-
tors of innate immunity. Depletion of PIAS4 would thus be ex-
pected to increase IFN and ISG production and further restrict
replication of IFN-sensitive viruses. Partially consistent with this
concept, type I IFN is upregulated in PIAS4/mouse embryonic
fibroblasts (MEFs) (78), while STAT1 or NF-B gene activation is
not detectably altered (43). Even with the variable effects of PIAS4
knockdown on innate immune signaling, Sendai virus replication
was further restricted in PIAS4/MEFs (78). In contrast, deple-
tion of PIAS4 in HFt cells enhanced the replication of ICP0-null
mutant HSV-1. This observation was somewhat unexpected, as
ICP0-null mutant HSV-1 is hypersensitive to repression by innate
immunity (91, 92). However, the assay used to evaluate the PFE of
HSV-1 in PIAS4 depleted cells is likely biased toward intrinsic,
rather than innate, immunity. As the PFE assay largely measures
the productivity of the initial infection event, the IFN response is
likely too slow to impede viral replication given that signaling
pathway activation and ISG synthesis are required to mount a
successful defense. Therefore, intrinsic immunity-mediated re-
pression likely largely underlies any PFE defects. Consistent with
this proposal, the PFE of ICP0-null mutant HSV-1 is not en-
hanced in cells with impaired innate immunity, achieved through
depletion of STAT1 or IRF3, while it is enhanced in cells with
impaired intrinsic immunity (10, 18, 50, 93, 94). Our identifica-
tion of PIAS4 as a component of the intrinsic antiviral immune
response suggests that PIAS proteinsmay sit at a crux of regulation
to relate intrinsic and innate immunity. It is conceivable that a
factor that positively regulates intrinsic immunity would down-
regulate innate immunity to limit situations in which a positive
feedback loop enhances the overall immune response such that it
cannot be curtailed following successful clearance or repression of
the invading pathogen. We have also recently identified PIAS1 as
an intrinsic antiviral factor (unpublished data), suggesting that
the complementary and cooperative roles of PIAS proteins in the
repression of innate immunity may be mirrored in the activation
of intrinsic immunity. Further characterization of the roles of
PIAS4 in immune regulation will identify how it balances regula-
tion of the innate and intrinsic immune responses and highlight
points that may be manipulated in the future to facilitate cellular
clearance or silencing of viral pathogens.
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